The firm is conducting validation studies on its lung cancer test and continues to anticipate commercializing it in the second half of this year.
Investigators from a variety of clinical sites found that the company's liquid biopsy test was more successful in finding actionable mutations in patients than tumor tissue.
The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.
The test is designed to measure levels of seven auto-antibodies to tumor-associated antigens and can detect all forms of lung cancer at any stage.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
VolitionRx's platform uses the company's Nucleosomics technology for identifying and quantifying nucleosome structural features such as histone modifications.
Funds raised will help accelerate commercialization of the firm's InVisionFirst-Lung liquid biopsy test and support development of the firm's platform for new indications
The partners will develop patient-specific assays based on ArcherDx's anchored multiplex PCR technology to track disease recurrence in lung cancer patients.
The two organizations will first focus on developing and validating Breath Diagnostics' OneBreath platform for lung cancer.
With deep learning software running on a supercomputer, Paige.AI is developing pathology technology that learns from large-scale digital image datasets.